Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02448446 · ClinicalTrials.gov registry record · Phase 1
The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
A Phase 1 study of Diabetic Macular Edema and Hard Lipid Exudates, sponsored by South Coast Retina Center; Carson, McBeath, Boswell.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 4
- Study locations
NCT02448446 is a Phase 1 study of Diabetic Macular Edema and Hard Lipid Exudates that has completed, run by South Coast Retina Center; Carson, McBeath, Boswell. The registered enrollment target is 25 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT02448446, a Phase 1 study of Diabetic Macular Edema and Hard Lipid Exudates, has completed, sponsored by South Coast Retina Center; Carson, McBeath, Boswell.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab in subjects with diabetic macular edema and lipid exudates in the central subfield.
Conditions Studied
Interventions
- DRUG ranibizumab 0.3mg
Study Locations (4)
California
- South Coast Retina Center; Carson, McBeath, Boswell, Inc - Huntington Beach
- South Coast Retina Center; Carson, McBeath, and Boswell, Inc - Long Beach
- Retina Partners - Santa Monica
- South Coast Retina Center; Carson, McBeath, Boswell, Inc - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02448446
The ClinicalTrials.gov registry entry for NCT02448446 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is South Coast Retina Center; Carson, McBeath, Boswell, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which ranibizumab 0.3mg is the first listed.
NCT02448446 reports 4 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02448446 about?
NCT02448446 is a clinical study titled "The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates". This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab in subjects with diabetic macular edema and lipid exudates in the central subfield.
What is the current status of trial NCT02448446?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-08. Estimated completion is 2018-05.
What conditions does trial NCT02448446 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Hard Lipid Exudates.
What interventions are being tested in trial NCT02448446?
The interventions under investigation include: ranibizumab 0.3mg (DRUG).
Who is sponsoring clinical trial NCT02448446?
This trial is sponsored by South Coast Retina Center; Carson, McBeath, Boswell, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02448446 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.